🏥 Health
1d ago
Post-Marketing Studies Document Extra VTE Risk for Baricitinib
Source ↗
👁 0
💬 0
(MedPage Today) -- LONDON -- Baricitinib (Olumiant) failed to show noninferiority to tumor necrosis factor (TNF) inhibitors for venous thromboembolism (VTE) risk in FDA-required postmarketing studies, a researcher reported here.
In two large...
In two large...
Comments (0)